Brain Imaging Devices Market Summary
The brain imaging devices market is expected to increase from USD 5,091.71 million in 2024 to USD 7,779.85 million by 2032, reflecting strong and sustained growth. The global brain imaging devices market is growing at a CAGR of 5.50% during the forecast period from 2025 to 2032. North America leads the global brain imaging devices market, accounting for approximately 41% of the total market share in 2024, driven by the high prevalence of neurological disorders, strong R&D investments, and advanced healthcare infrastructure.
Speak With Our Expert Analyst Today to Get Brain Imaging Devices Market Report
Brain Imaging Devices Overview
Brain imaging devices are advanced diagnostic tools used to visualize the structure and function of the brain, playing a crucial role in detecting and monitoring neurological disorders such as Alzheimer’s, stroke, epilepsy, Parkinson’s disease, and brain tumors. Key modalities include MRI, CT, PET, EEG, and MEG, each offering unique capabilities for structural, functional, and metabolic imaging.
The market is growing rapidly, fueled by rising neurological disease prevalence, an aging population, and continuous technological advancements such as AI-powered imaging, portable MRI systems, and hybrid PET/MRI platforms. These innovations are improving diagnostic accuracy, enabling early detection, and expanding access to high-quality neuroimaging across both developed and emerging healthcare systems.
The global brain imaging devices market is driven by the rising prevalence of neurological disorders, technological advancements – especially AI and ML integration – and increasing product development activities by key market players, including innovations in MRI, CT, and PET technologies.
Brain Imaging Devices Diagnosis
Brain imaging devices serve as essential diagnostic instruments across a broad spectrum of neurological conditions. Neurological conditions such as Alzheimer’s disease, Parkinson’s disease, epilepsy, stroke, multiple sclerosis, and brain tumors are increasing globally, primarily due to aging populations and lifestyle-related risk factors like obesity, stress, and cardiovascular disease. These disorders require accurate diagnosis and continuous monitoring, making brain imaging devices such as MRI, CT, and PET scanners essential.
MRI helps detect brain shrinkage in Alzheimer’s, while CT and PET are crucial for stroke detection and tumor evaluation. According to DelveInsight analysis, more than 7.5 million people in the U.S. were living with Alzheimer’s disease in the reported year, with the number projected to nearly double to 13 million by 2050. Brain imaging plays a vital role in detecting Alzheimer-related changes such as hippocampal shrinkage, cortical thinning, and the accumulation of harmful proteins like amyloid and tau.
Around 50.5 million people worldwide are affected by epilepsy, with nearly 80% residing in low- and middle-income countries. Brain imaging modalities such as MRI, CT, and PET scans play a crucial role in detecting structural abnormalities, lesions, tumors, or scarring responsible for seizures. Similarly, nearly 21 million people globally are living with intracerebral hemorrhage (ICH), where rapid and precise imaging is essential to identify the location, size, and cause of bleeding, guide urgent medical or surgical interventions, and distinguish ICH from ischemic stroke.
Brain Imaging Devices Treatment
Advanced brain imaging technologies underpin treatment planning and therapeutic monitoring across neurological indications. Brain tumors require precise visualization of their size, location, and impact on surrounding brain structures, making modalities such as MRI, CT, and PET indispensable. MRI, in particular, is considered the gold standard for brain tumor detection because of its superior soft tissue contrast, enabling detailed assessment of tumor boundaries and infiltration.
With an increasing number of patients requiring surgical intervention, radiation therapy, and ongoing monitoring, the demand for high-resolution and functional imaging systems continues to grow. Functional MRI also plays an essential role in pre-surgical planning and cognitive research, highlighting brain activity patterns with precision. Modalities such as MRI and PET – particularly amyloid PET and tau PET – are extensively used in clinical and research settings to identify early markers of neurodegeneration, track disease progression, and assess treatment efficacy.
Despite the growing demand, the brain imaging devices market faces several restraints. One of the primary challenges is the high cost of equipment and ongoing maintenance, as advanced imaging modalities like MRI, CT, and PET scanners require significant capital investment, specialized infrastructure, and continuous servicing. Another concern is the risk of radiation exposure associated with modalities such as CT and PET, which raises patient safety issues, especially for vulnerable groups requiring repeated scans.
Download a Free Sample Report to Explore Brain Imaging Devices Market Size and Forecast
Brain Imaging Devices Drug Analysis
The brain imaging devices market report provides a comprehensive evaluation of leading and emerging products across major imaging modalities. The report covers detailed market segmentation by Product Type (Devices [Magnetic Resonance Imaging (MRI), Computed Tomography (CT/SPECT), Positron Emission Tomography (PET), and Others] and Accessories & Consumables), Portability (Stationary and Portable), Application (Stroke, Brain Tumor, Epilepsy, and Others), End-User (Hospitals, Diagnostic Imaging Centers, Ambulatory Surgery Centers, and Others), and Geography.
Brain Imaging Devices Marketed Therapies
Magnetic Resonance Imaging (MRI): Dominant Modality
MRI devices hold the largest share within the devices category, driven by their wide-ranging advantages and clinical applications. MRI provides high-resolution, detailed images of internal body structures, particularly soft tissues that are often difficult to visualize with other imaging modalities such as X-ray or CT. Unlike CT scans, MRI does not use ionizing radiation, making it a safer option for repeated examinations, especially for vulnerable populations like children and pregnant women.
Its superior contrast resolution allows for clear differentiation between tissues such as gray and white matter, muscles, fat, and ligaments. Advanced techniques such as contrast-enhanced MRI and functional MRI (fMRI) further extend its utility by visualizing blood flow, mapping neural activity, and supporting functional assessments.
At RSNA in November 2024, Philips introduced its next-generation 1.5T BlueSeal MRI – the industry’s first wide-bore, helium-free scanner with full AI integration. Incorporating advanced features such as SmartExam, SmartSpeed, and zero-click AI reporting, the system delivers faster, high-resolution imaging and automated diagnostics.
Computed Tomography (CT/SPECT) and Positron Emission Tomography (PET)
CT and PET systems remain critical imaging tools for neurological applications, particularly in emergency care and oncology. CT is indispensable in emergency settings for monitoring hematoma development and treatment response in conditions such as ICH and ischemic stroke. In December 2024, Canon Medical Systems USA expanded its AI-enabled CT portfolio by launching tools such as INSTINX and Vitrea, designed to accelerate diagnostic processes and improve clinical accuracy. The portfolio also featured a Stroke CT Package with specialized applications for intracerebral hemorrhage (ICH), large vessel occlusion (LVO), and CT brain perfusion.
PET imaging, particularly hybrid PET/MRI platforms, continues to gain traction for its comprehensive diagnostic utility. Leading companies including Philips, Siemens Healthineers, GE Healthcare, and Canon Medical Systems dominate the market through extensive product portfolios, along with strong global distribution networks.
Brain Imaging Devices Emerging Therapies
AI and ML-Integrated Imaging Platforms
The integration of AI and ML is accelerating market momentum by refining diagnostic precision and streamlining clinical workflows. AI-powered tools can detect subtle abnormalities, automate image segmentation, and even predict disease progression, supporting earlier and more personalized treatment decisions. AI-integrated MRI and PET systems are now capable of identifying amyloid and tau protein deposits linked to Alzheimer’s disease.
Companies such as Hyperfine with its Swoop® Portable MRI, Philips with Smart Quant Neuro 3D, and Fujifilm with ECHELON Synergy are embedding AI capabilities into MRI, CT, and PET platforms to optimize image quality and automate reporting. In September 2025, Hyperfine announced that its Optive AI™ software received both CE Marking and UK Conformity Assessment (UKCA) approval. In March 2025, Hyperfine partnered with NVIDIA to enhance the artificial intelligence capabilities of its Swoop Portable MRI system – recognized as the world’s first FDA-approved portable magnetic resonance brain imaging device.
Portable and Hybrid Imaging Innovations
Leading medical device companies and startups are heavily investing in the development of innovative brain imaging solutions, including portable MRI devices for point-of-care diagnostics, hybrid PET/MRI platforms for more comprehensive imaging, and advanced CT systems with low-dose radiation and faster scanning capabilities. Workflow automation enabled by AI reduces clinician workload, improves efficiency, and expands access to imaging services, particularly in high-volume hospitals and tele-radiology platforms. These continuous product launches and regulatory approvals not only expand clinical utility but also increase adoption across hospitals, diagnostic centers, and research institutes.
Brain Imaging Devices Epidemiology
The brain imaging devices epidemiology section provides historical as well as forecasted data across major geographies including North America, Europe, Asia-Pacific, and the Rest of the World through 2032.
Key findings include:
- More than 7.5 million people in the U.S. were living with Alzheimer’s disease in the reported year, with the number projected to nearly double to 13 million by 2050; approximately one in nine individuals aged 65 and above is affected, with women facing a higher risk.
- As of 2023, nearly one million people in the U.S. were living with a brain tumor, with both malignant and benign tumors requiring high-resolution imaging for surgical planning, radiation therapy, and ongoing monitoring.
- Around 50.5 million people worldwide are affected by epilepsy, with nearly 80% residing in low- and middle-income countries, driving reliance on advanced brain imaging for accurate diagnosis.
- Nearly 21 million people globally are living with intracerebral hemorrhage (ICH), where rapid and precise imaging through CT and MRI is essential for emergency management and treatment monitoring.
Brain Imaging Devices Market Outlook
During the forecast period (2025–2032), the global brain imaging devices market is expected to grow from USD 5,091.71 million in 2024 to USD 7,779.85 million by 2032 at a CAGR of 5.50%. North America dominates the global brain imaging devices market, accounting for approximately 41% of the total market share in 2024, driven by the high prevalence of neurological disorders, strong R&D investment, advanced healthcare infrastructure, and continuous innovation by leading medical device companies.
The Europe brain imaging devices market is witnessing strong growth driven by rising cases of neurological disorders such as Alzheimer’s disease, dementia, stroke, and epilepsy, increasingly prevalent in the region’s aging population. Governments and healthcare systems across Europe are investing heavily in early diagnosis and advanced neuroimaging infrastructure, supported by favorable reimbursement frameworks in countries like Germany, France, and the U.K.
The Asia-Pacific brain imaging devices market is witnessing rapid expansion, reflecting a robust CAGR of 6.87% during the forecast period from 2025 to 2032. Countries such as China, Japan, India, and South Korea are emerging as key contributors, with expanding hospital infrastructure, government initiatives for early diagnosis, and growing awareness about brain health fueling demand. Japan continues to lead in technological innovation with strong adoption of high-end MRI and PET systems, while China is rapidly expanding its domestic manufacturing capabilities to reduce reliance on imports.
The competitive landscape is characterized by a high degree of market concentration with the presence of leading global medical technology companies, specialized imaging firms, and emerging innovators focusing on AI-driven solutions. Strategic collaborations, mergers and acquisitions, and partnerships with research institutions are increasingly shaping competition, as firms seek to expand their clinical applications in neurology, oncology, and psychiatry.
Get Detailed Insights on Brain Imaging Devices Market – Request a Custom Report Today
Conclusion
The brain imaging devices market is poised for substantial transformation through 2032, driven by advances in imaging technologies, increasing disease recognition, and a robust landscape of innovative solutions targeting unmet clinical needs. While established modalities such as MRI, CT, and PET continue to dominate current clinical practice, emerging approaches such as AI-powered imaging platforms, portable MRI systems, and hybrid PET/MRI technologies hold the potential to redefine diagnostic accuracy and patient outcomes. Growing awareness among healthcare providers, improved access to specialized imaging infrastructure, and expanding research efforts across neurological indications are expected to accelerate market growth. Collectively, these factors position the brain imaging devices landscape for sustained evolution and diagnostic progress through 2032.
About DelveInsight
DelveInsight is a leading Healthcare Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharmaceutical companies by providing comprehensive end-to-end solutions to improve their performance. It also offers healthcare consulting services that leverage market analysis to accelerate business growth and overcome challenges with practical approaches.
Media contact
Name: Abhishek kumar
E-mail: abhishek@delveinsight.com
